These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 21760581)

  • 1. Biomarkers: warning signs.
    Williams R
    Nature; 2011 Jul; 475(7355):S5-7. PubMed ID: 21760581
    [No Abstract]   [Full Text] [Related]  

  • 2. Beyond diagnosis: what biomarkers are teaching us about the "bio"logy of Alzheimer disease.
    Rabinovici GD; Roberson ED
    Ann Neurol; 2010 Mar; 67(3):283-5. PubMed ID: 20373338
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomarkers reflecting different facets of Alzheimer's disease.
    Zetterberg H
    Eur J Neurol; 2008 Nov; 15(11):1143-4. PubMed ID: 18973609
    [No Abstract]   [Full Text] [Related]  

  • 4. Alzheimer's disease is getting easier to spot.
    Dolgin E
    Nature; 2018 Jul; 559(7715):S10-S12. PubMed ID: 30046081
    [No Abstract]   [Full Text] [Related]  

  • 5. The utility of the new research diagnostic criteria for Alzheimer's disease.
    Dubois B; Gauthier S; Cummings J
    Int Psychogeriatr; 2013 Feb; 25(2):175-7. PubMed ID: 23148941
    [No Abstract]   [Full Text] [Related]  

  • 6. Biomarkers, assays, and therapies for Alzheimer disease.
    Beriault DR; Diamandis EP; Portelius E; Perret-Liaudet A; Salloway S
    Clin Chem; 2015 Jul; 61(7):903-8. PubMed ID: 26015517
    [No Abstract]   [Full Text] [Related]  

  • 7. Alzheimer's: forestalling the darkness.
    Stix G
    Sci Am; 2010 Jun; 302(6):50-7. PubMed ID: 20521480
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset.
    Altomare D; Ferrari C; Caroli A; Galluzzi S; Prestia A; van der Flier WM; Ossenkoppele R; Van Berckel B; Barkhof F; Teunissen CE; Wall A; Carter SF; Schöll M; Choo ILH; Grimmer T; Redolfi A; Nordberg A; Scheltens P; Drzezga A; Frisoni GB;
    J Neurol; 2019 Oct; 266(10):2535-2545. PubMed ID: 31267207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of biomarkers in clinical trials for Alzheimer disease.
    Thal LJ; Kantarci K; Reiman EM; Klunk WE; Weiner MW; Zetterberg H; Galasko D; Praticò D; Griffin S; Schenk D; Siemers E
    Alzheimer Dis Assoc Disord; 2006; 20(1):6-15. PubMed ID: 16493230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.
    Chételat G; Villemagne VL; Bourgeat P; Pike KE; Jones G; Ames D; Ellis KA; Szoeke C; Martins RN; O'Keefe GJ; Salvado O; Masters CL; Rowe CC;
    Ann Neurol; 2010 Mar; 67(3):317-24. PubMed ID: 20373343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease.
    Prvulovic D; Hampel H
    Clin Chem Lab Med; 2011 Mar; 49(3):367-74. PubMed ID: 21342022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Biomarker and imaging of Alzheimer's disease].
    Kawarabayashi T; Shoji M
    No To Shinkei; 2005 Oct; 57(10):839-52. PubMed ID: 16277229
    [No Abstract]   [Full Text] [Related]  

  • 13. Alzheimer disease.
    Castellani RJ; Rolston RK; Smith MA
    Dis Mon; 2010 Sep; 56(9):484-546. PubMed ID: 20831921
    [No Abstract]   [Full Text] [Related]  

  • 14. Biopsy support for the validity of Pittsburgh compound B positron emission tomography with a twist.
    Klunk WE
    Arch Neurol; 2008 Oct; 65(10):1281-3. PubMed ID: 18852340
    [No Abstract]   [Full Text] [Related]  

  • 15. [Amyloid and tau imaging, its present and future].
    Okamura N; Harada R; Kudo Y; Yanai K
    Nihon Yakurigaku Zasshi; 2015 Sep; 146(3):144-9. PubMed ID: 26354014
    [No Abstract]   [Full Text] [Related]  

  • 16. Quantification of Tau Load in Alzheimer's Disease Clinical Trials Using Positron Emission Tomography.
    Timmers T; van Berckel BNM; Lammertsma AA; Ossenkoppele R
    Methods Mol Biol; 2018; 1750():221-229. PubMed ID: 29512076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccines: chasing the dream.
    Schnabel J
    Nature; 2011 Jul; 475(7355):S18-9. PubMed ID: 21760578
    [No Abstract]   [Full Text] [Related]  

  • 18. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between tau deposition and antecedent amyloid-β accumulation rates in normal and early symptomatic individuals.
    Tosun D; Landau S; Aisen PS; Petersen RC; Mintun M; Jagust W; Weiner MW;
    Brain; 2017 May; 140(5):1499-1512. PubMed ID: 28334939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma tau/amyloid-β1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer's disease.
    Park JC; Han SH; Yi D; Byun MS; Lee JH; Jang S; Ko K; Jeon SY; Lee YS; Kim YK; Lee DY; Mook-Jung I
    Brain; 2019 Mar; 142(3):771-786. PubMed ID: 30668647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.